S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Amgen Inc [AMGN]

Børs: NASDAQ Sektor: Healthcare Industri: Drug Manufacturers—General
Upcoming Earnings Alert

4 days till quarter result
(amc 2024-05-02)

Expected move: +/- 2.37%

BUY
51.02%
return -0.44%
SELL
36.00%
return 7.27%
Sist oppdatert26 apr 2024 @ 22:00

0.22% $ 269.98

KJøP 1759 min ago

@ $270.69

Utstedt: 26 apr 2024 @ 21:51


Avkastning: -0.26%


Forrige signal: apr 26 - 19:55


Forrige signal: Selg


Avkastning: -0.03 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):
Profile picture for Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...

Stats
Dagens volum 2.44M
Gjennomsnittsvolum 2.95M
Markedsverdi 144.69B
EPS $0 ( 2024-04-25 )
Neste inntjeningsdato ( $3.76 ) 2024-05-02
Last Dividend $2.25 ( 2024-02-15 )
Next Dividend $0 ( N/A )
P/E 21.60
ATR14 $5.96 (2.21%)
Insider Trading
Date Person Action Amount type
2024-03-18 Santos Esteban Sell 6 137 Common Stock
2024-03-18 Reese David M Sell 6 202 Common Stock
2024-03-18 Miller Derek Sell 475 Common Stock
2024-03-18 Khosla Rachna Sell 438 Common Stock
2024-03-18 Grygiel Nancy A. Sell 703 Common Stock
INSIDER POWER
58.82
Last 97 transactions
Buy: 472 102 | Sell: 97 922

Volum Korrelasjon

Lang: -0.56 (weak negative)
Kort: -0.27 (neutral)
Signal:(30) Neutral

Amgen Inc Korrelasjon

10 Mest positive korrelasjoner
SMIT0.929
CNCE0.926
PLIN0.925
CTIC0.921
RETA0.921
LAWS0.921
PIII0.917
IMTX0.914
OP0.913
OBT0.912
10 Mest negative korrelasjoner
RGLD-0.945
GRFS-0.941
IMVT-0.939
WB-0.936
HCM-0.934
HERA-0.934
SOCL-0.933
HOFT-0.933
IPKW-0.93
HERAU-0.929

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Amgen Inc Korrelasjon - Valuta/Råvare

The country flag -0.20
( neutral )
The country flag -0.20
( neutral )
The country flag 0.00
( neutral )
The country flag -0.16
( neutral )
The country flag 0.01
( neutral )
The country flag -0.11
( neutral )

Amgen Inc Økonomi

Annual 2023
Omsetning: $28.19B
Bruttogevinst: $19.74B (70.02 %)
EPS: $12.56
FY 2023
Omsetning: $28.19B
Bruttogevinst: $19.74B (70.02 %)
EPS: $12.56
FY 2022
Omsetning: $26.32B
Bruttogevinst: $19.92B (75.66 %)
EPS: $12.18
FY 2021
Omsetning: $25.98B
Bruttogevinst: $19.53B (75.16 %)
EPS: $10.06

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$1.940
(N/A)
$1.940
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.13
(N/A)
$2.25
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Amgen Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.55 - Stable (31.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.280 2011-08-16
Last Dividend $2.25 2024-02-15
Next Dividend $0 N/A
Payout Date 2024-03-07
Next Payout Date N/A
# dividends 51 --
Total Paid Out $61.13 --
Avg. Dividend % Per Year 2.40% --
Score 5.46 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 6.55
Div. Directional Score 8.29 --
Next Divdend (Est)
(2024-07-01)
$2.30 Estimate 61.99 %
Dividend Stability
0.99 Excellent
Dividend Score
5.46
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2011 $0.560 1.01%
2012 $1.440 2.25%
2013 $1.880 2.11%
2014 $2.44 2.11%
2015 $3.16 1.98%
2016 $4.00 2.53%
2017 $4.60 3.05%
2018 $5.28 2.98%
2019 $5.80 3.02%
2020 $6.40 2.67%
2021 $7.04 3.11%
2022 $7.76 3.42%
2023 $8.52 3.26%
2024 $2.25 0.76%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2381.5005.237.85[0 - 0.5]
returnOnAssetsTTM0.06911.2007.709.23[0 - 0.3]
returnOnEquityTTM1.0331.50010.0010.00[0.1 - 1]
payoutRatioTTM0.678-1.0003.22-3.22[0 - 1]
currentRatioTTM1.6490.8006.755.40[1 - 3]
quickRatioTTM1.6220.8005.174.13[0.8 - 2.5]
cashRatioTTM0.5951.5007.8110.00[0.2 - 2]
debtRatioTTM0.665-1.50010.00-10.00[0 - 0.6]
interestCoverageTTM3.151.0009.949.94[3 - 30]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
freeCashFlowPerShareTTM13.762.003.126.24[0 - 20]
debtEquityRatioTTM10.37-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.7001.0001.6631.663[0.2 - 0.8]
operatingProfitMarginTTM0.3211.0005.575.57[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1311.000-0.383-0.383[0.2 - 2]
assetTurnoverTTM0.2900.800-1.399-1.119[0.5 - 2]
Total Score10.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM21.501.0007.930[1 - 100]
returnOnEquityTTM1.0332.503.3410.00[0.1 - 1.5]
freeCashFlowPerShareTTM13.762.005.416.24[0 - 30]
dividendYielPercentageTTM3.201.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
payoutRatioTTM0.6781.5003.22-3.22[0 - 1]
pegRatioTTM0.6221.5009.190[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3001.0004.990[0.1 - 0.5]
Total Score6.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.